←Back to Expert Scholars
Translational Medicine / 转化医学Bispecific T Cell Engagers
Mark Cobbold
PhD
🏢AstraZeneca🌐USA
Vice President, Immuno-Oncology
60
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Mark Cobbold leads bispecific antibody and T cell engager development including platforms targeting MHC-presented neoantigens. His work has advanced multiple cancer bispecific antibodies toward clinical translation for solid tumors.
Share:
🧪Research Fields 研究领域
T cell engager
bispecific antibody cancer
BiTE technology
solid tumor bispecific
antibody engineering
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Mark Cobbold 的研究动态
Follow Mark Cobbold's research updates
留下邮箱，当我们发布与 Mark Cobbold（AstraZeneca）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment